Module information
Module details
- Title
- Haematological Oncology
- Type
- Specialist
- Module code
- S-CI-S4
- Credits
- 10
- Phase
- 3
- Requirement
- Compulsory
Aim of this module
This module aims to provide trainees with knowledge and understanding of the presentation, diagnostic tests and clinical urgency of investigating patients with suspected haematological malignancies.
Work-based content
Training activities
| # | Learning outcome | Training activity | Type | Action |
|---|---|---|---|---|
| # 1 | Learning outcome 1, 2, 3 |
Training activities
Select the appropriate immunological assay to investigate individuals with potential plasma cell dyscrasia |
Type ETA | Action View |
| # 2 | Learning outcome 1, 2, 3 |
Training activities
Perform and analyse the following immunological investigations:
|
Type ETA | Action View |
| # 3 | Learning outcome 1, 2, 3 |
Training activities
Identify potential haematological malignancies from routine flow cytometry immunology investigations |
Type DTA | Action View |
| # 4 | Learning outcome 2, 3 |
Training activities
Recommend appropriate actions following the identification of an aberrant population on routine immunology flow cytometry, and determine further testing where suitable and escalate as appropriate |
Type DTA | Action View |
| # 5 | Learning outcome 2 |
Training activities
Interpret flow cytometry data for an initial diagnostic screening panel for the following conditions:
|
Type DTA | Action View |
| # 6 | Learning outcome 4 |
Training activities
Identify relevant clinical investigations for myeloma from other disciplines that will impact on the interpretation of the immunological investigation |
Type ETA | Action View |
| # 7 | Learning outcome 2, 3, 4 |
Training activities
Draft reports including interpretive clinical comments in light of clinical details and associated laboratory results for the following immunological investigations:
|
Type ETA | Action View |
| # 8 | Learning outcome 1, 2, 3 |
Training activities
Interpret and problem solve EQA for a range of assays involved in assessing potential plasma cell dyscrasia including an example of investigating concerns with EQA performance |
Type DTA | Action View |
| # 9 | Learning outcome 1, 3 |
Training activities
Resolve a technical issue for two of the following:
|
Type DTA | Action View |
| # 10 | Learning outcome 2, 4 |
Training activities
Determine clinical urgency of new abnormal findings and appropriate methods of communication with the clinical team |
Type ETA | Action View |
Assessments
Complete 2 Case-Based Discussions
Complete 2 DOPS or OCEs
Direct Observation of Practical Skills Titles
- Perform and analyse serum electrophoresis and/or capillary zone electrophoresis on patients with suspected haematological malignancies.
- Perform and analyse a cryoglobulin test.
- Perform the serum free light chain assay.
- Interpret a returned EQA report for a scheme relevant to laboratory tests used for haematological malignancies.
Observed Clinical Event Titles
- Communicate results to another healthcare professional and recommend next steps for a patient with a sample that has an aberrant population detected on routine flow.
- Gather a patient history from another healthcare professional.
- Communicate results to another healthcare professional and recommend next steps on a patient with new monoclonal gammopathy.
Learning outcomes
| # | Learning outcome |
|---|---|
| 1 | Perform laboratory investigations on samples from patients with suspected haematological malignancies. |
| 2 | Analyse, interpret and report on laboratory investigations for haematological malignancies, including recognition of abnormal results. |
| 3 | Summarise the limitations of methods used to aid diagnosis of haematological malignancies. |
| 4 | Practice in partnership with other clinical specialisms in the investigation of haematological malignancies. |
Clinical experiences
Clinical experiences help you to develop insight into your practice and a greater understanding of your specialty's impact on patient care. Clinical experiences should be included in your training plan and you may be asked to help organise your experiences. Reflections and observations from your experiences may help you to advance your practice and can be used to develop evidence to demonstrate your awareness and appreciation of your specialty.
Activities
- Attend multidisciplinary team meetings for an appropriate clinical specialty.
- Observe input into an integrated report at a haematology diagnostic service.
- Attend a clinic for an appropriate clinical specialty.
- Attend an event where patients discuss their experiences, using reflective practice.
Academic content (MSc in Clinical Science)
Important information
The academic parts of this module will be detailed and communicated to you by your university. Please contact them if you have questions regarding this module and its assessments. The module titles in your MSc may not be exactly identical to the work-based modules shown in the e-portfolio. Your modules will be aligned, however, to ensure that your academic and work-based learning are complimentary.
Learning outcomes
On successful completion of this module the trainee will be able to:
- Describe and explain the underlying pathogenesis of a range of haematological malignancies.
- Demonstrate a critical awareness of classification of haematological malignancies as defined by WHO international guidelines.
- Critically evaluate the design, operation and performance of diagnostic assays used in the investigation and monitoring of haematological malignancies.
- Critically appraise the therapeutic approaches used in clinical management of haematological malignancies.
- Explain the importance of integrated diagnosis and the implementation of national and international guidelines on the diagnosis and management of haematological malignancies.
Indicative content
- Current understanding of the clinical features, pathogenesis, molecular mechanisms, diagnosis and management of:
- Myeloid malignancies
- Lymphoid leukaemia
- Lymphoma
- Myeloma and plasma cell disorders
- Myelodysplastic syndromes
- Myeloproliferative disorders
- Bone marrow failure syndromes
- Introduction to the classification of haematological malignancies according to the WHO.
- Characteristic morphology and/or immunophenotype of each disease.
- Molecular and genetic techniques for the detection of pathogenetic variants.
- Approaches for the monitoring of response to therapy including residual disease.
- Current approaches to treatment of haematological malignancies and their mechanism of action to include: chemotherapy, immunotherapy, targeted therapy and stem cell transplant.
- National and international guidelines for diagnosis and management of myeloid and lymphoid malignancies (NICE, BCSH, ELN, WHO).